Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Cupid has been allocated approximately 23.4 million units of female condoms per year
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Subscribe To Our Newsletter & Stay Updated